托吡酯
医学
丙戊酸
耐受性
偏头痛
慢性偏头痛
临床试验
知情同意
家庭医学
精神科
内科学
替代医学
不利影响
癫痫
病理
作者
Michel Dominique Ferrari,Karin W.M. Zuurbier,Steve Barash,Xiaoping Ning,Joshua M. Cohen
出处
期刊:Headache
[Wiley]
日期:2022-04-01
卷期号:62 (4): 530-533
被引量:10
摘要
Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid INTRODUC TI ONFremanezumab, a humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide, is approved in Europe, the United States, and many other countries for the prevention of migraine attacks in adults.1,2 In some countries, prior
科研通智能强力驱动
Strongly Powered by AbleSci AI